cadonilimab   Click here for help

GtoPdb Ligand ID: 12966

Synonyms: AK-104 | AK104
Approved drug Immunopharmacology Ligand
cadonilimab is an approved drug (China NMPA (2022))
Compound class: Antibody
Comment: Cadonilimab (AK104) is a humanized, bispecific monoclonal antibody that simultaneously targets the immune checkpoint proteins PD-1 and CTLA-4. It was designed as a cancer immunotherapy (immuno-oncology) agent.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
Bioactivity Comments
Cadonilimab does not bind to Fc receptors so exhibits minimal effector functions, and has no effect on interleukin-6 (IL-6)/IL-8 release.
Selectivity at other protein targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
programmed cell death 1 (CD279) Primary target of this compound Hs Antibody Binding 10.3 pEC50 - 2
⤷ pEC50 10.3 (EC50 5.1x10-11 M) [2]
Description: Antigen binding potency determined by ELISA
cytotoxic T-lymphocyte-associated protein 4 (CD152) Primary target of this compound Hs Antibody Binding 10.1 pEC50 - 2
⤷ pEC50 10.1 (EC50 7.9x10-11 M) [2]
Description: Antigen binding potency determined by ELISA